{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T08:30:32Z","timestamp":1776501032661,"version":"3.51.2"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejves.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Vascular and Endovascular Surgery"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejvs.2026.01.043","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:25:57Z","timestamp":1769732757000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Impacts of Sodium\u2013Glucose Co-Transporter 2 Inhibitors in Diabetic Patients with Chronic Limb Threatening Ischaemia Undergoing Endovascular Therapy: Results of the SIRIUS Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-473X","authenticated-orcid":false,"given":"Tatsuro","family":"Takei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7764-2165","authenticated-orcid":false,"given":"Shunsuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-1277","authenticated-orcid":false,"given":"Takashi","family":"Yanagiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9107-6438","authenticated-orcid":false,"given":"Tatsuya","family":"Nakama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yanagiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Nakama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejvs.2026.01.043_bib1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jvs.2013.08.003","article-title":"The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on Wound, Ischemia, and foot Infection (WIfI)","volume":"59","author":"Mills","year":"2014","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejvs.2026.01.043_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.avsg.2023.02.010","article-title":"Risk factors for major amputation in chronic limb-threatening ischemia patients classified as Wound, Ischemia, and foot Infection stage 4 following infrainguinal revascularization","volume":"94","author":"Morisaki","year":"2023","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.ejvs.2026.01.043_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s42155-024-00443-9","article-title":"Poor short-term outcomes for prognostic high-risk patients with chronic limb-threatening ischemia undergoing endovascular therapy","volume":"7","author":"Takei","year":"2024","journal-title":"CVIR Endovasc"},{"key":"10.1016\/j.ejvs.2026.01.043_bib4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jvs.2024.12.128","article-title":"Outcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial","volume":"81","author":"Malas","year":"2025","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejvs.2026.01.043_bib5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ejvs.2024.12.038","article-title":"Editor\u2019s Choice \u2013 Delays to revascularisation and outcomes of non-elective admissions for chronic limb threatening ischaemia: a UK population based cohort study","volume":"69","author":"Birmpili","year":"2025","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2026.01.043_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.5551\/jat.57711","article-title":"Risk stratification for 2-year mortality in patients with chronic limb-threatening ischemia undergoing endovascular therapy","volume":"28","author":"Hata","year":"2021","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ejvs.2026.01.043_bib7","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejvs.2026.01.043_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejvs.2026.01.043_bib9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejvs.2026.01.043_bib10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejvs.2026.01.043_bib11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejvs.2026.01.043_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejvs.2026.01.043_bib13","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1210\/clinem\/dgac558","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock","volume":"107","author":"Li","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejvs.2026.01.043_bib14","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00210-023-02685-1","article-title":"Sodium\u2013glucose cotransporter-2 inhibitor in risk of sepsis\/septic shock among patients with type 2 diabetes mellitus\u2014a retrospective analysis of nationwide medical claims data","volume":"397","author":"Hu","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejvs.2026.01.043_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10787-020-00732-4","article-title":"Empagliflozin suppresses inflammation and protects against acute septic renal injury","volume":"29","author":"Maayah","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejvs.2026.01.043_bib16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bph.13741","article-title":"Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice","volume":"174","author":"\u00c5strand","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejvs.2026.01.043_bib17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program","volume":"138","author":"R\u00e5dholm","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejvs.2026.01.043_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.diabres.2019.05.028","article-title":"Peripheral artery disease and amputations with sodium\u2013glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized controlled trials","volume":"153","author":"Dicembrini","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ejvs.2026.01.043_bib19","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.13647","article-title":"Sodium\u2013glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: evolving questions, evolving answers","volume":"21","author":"Yang","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejvs.2026.01.043_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000520903","article-title":"Effects of sodium\u2013glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials","volume":"107","author":"See","year":"2022","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejvs.2026.01.043_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ejvs.2021.09.031","article-title":"Initiation of SGLT2 inhibitors and the risk of lower extremity minor and major amputation in patients with type 2 diabetes and peripheral arterial disease: a health claims data analysis","volume":"62","author":"Rodionov","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2026.01.043_bib22","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.ejvs.2026.01.043_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/1526602820966309","article-title":"A novel scoring system for small artery disease and medial arterial calcification is strongly associated with major adverse limb events in patients with chronic limb-threatening ischemia","volume":"28","author":"Ferraresi","year":"2021","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.ejvs.2026.01.043_bib24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jcin.2022.09.022","article-title":"Guideline-directed medical therapy and long-term mortality and amputation outcomes in patients undergoing peripheral vascular interventions","volume":"16","author":"Smolderen","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ejvs.2026.01.043_bib25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejvs.2026.01.043_bib26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejvs.2026.01.043_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejvs.2026.01.043_bib28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ejvs.2023.07.020","article-title":"Editor\u2019s Choice \u2013 The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes mellitus and a foot ulcer","volume":"66","author":"Fitridge","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2026.01.043_bib29","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jvs.2023.01.200","article-title":"Updated estimates for the burden of chronic limb-threatening ischemia in the Medicare population","volume":"77","author":"Kwong","year":"2023","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejvs.2026.01.043_bib30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1253\/circj.CJ-24-0830","article-title":"Efficacy of Rheocarna\u00ae, a novel apheresis device, in patients with no- or poor-option chronic limb-threatening ischemia","volume":"89","author":"Soga","year":"2025","journal-title":"Circ J"},{"key":"10.1016\/j.ejvs.2026.01.043_bib31","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/1744-9987.13991","article-title":"Clinical impact of a novel lipoprotein apheresis treatment on no-option chronic limb-threatening ischemia: result from the REDUCTION VISCOSITY study","volume":"27","author":"Kojima","year":"2023","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.ejvs.2026.01.043_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejvs.2026.01.043_bib33","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/eurheartj\/ehae207","article-title":"Lower extremity arterial disease vs. coronary artery disease: mortality differences after revascularization","volume":"45","author":"Takahara","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejvs.2026.01.043_bib34","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","article-title":"Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls","volume":"359","author":"Pocock","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejvs.2026.01.043_bib35","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ije\/dyy013","article-title":"Data maturity and follow-up in time-to-event analyses","volume":"47","author":"Gebski","year":"2018","journal-title":"Int J Epidemiol"}],"container-title":["European Journal of Vascular and Endovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078588426000791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078588426000791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:00:00Z","timestamp":1773817200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078588426000791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"alternative-id":["S1078588426000791"],"URL":"https:\/\/doi.org\/10.1016\/j.ejvs.2026.01.043","relation":{},"ISSN":["1078-5884"],"issn-type":[{"value":"1078-5884","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Impacts of Sodium\u2013Glucose Co-Transporter 2 Inhibitors in Diabetic Patients with Chronic Limb Threatening Ischaemia Undergoing Endovascular Therapy: Results of the SIRIUS Study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Vascular and Endovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejvs.2026.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Vascular Surgery. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}